18F-FDG-PET and Multimodal Biomarker Integration: A Powerful Tool for Alzheimer’s Disease Diagnosis

Résumé fourni par la source

Abstract An early, biomarker-based diagnosis of Alzheimer’s Disease (AD) is crucial, especially with the emerging availability of novel therapeutic options. However, the role of 18 F-FDG-PET and its relationship to other PET and CSF biomarkers remains unclear. Therefore, the aim of this study was the evaluation of the role of 18 F-FDG-PET in AD diagnosis and its relationship to other commonly used fluid and PET biomarkers and their individual and multimodal accuracy in AD diagnosis. We included n = 157 AD patients, n = 603 MCI patients, and n = 380 cognitively normal participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) that underwent PET imaging with 18 F-FDG or 18 F-Florbetapir. Clinical and imaging data including patient characteristics, CSF biomarkers, cognition tests, 18 F-FDG-PET, 18 F-Florbetapir-PET, and 18 F-Flortaucipir-PET were retrospectively analyzed. PET images were quantified in several brain regions. The uptake of 18 F-FDG was inversely correlated with 18 F-Florbetapir and positively correlated with CSF Aβ42 in several brain regions commonly affected by AD. Additionally, 18 F-FDG uptake showed an inverse correlation with both forms of CSF tau, t-tau and p-tau, in various brain regions, but did not correlate with 18 F-Flortaucipir uptake. Moreover, regional 18 F-FDG uptake was positively correlated with cognitive function. Diagnostic accuracies were similarly high for 18 F-FDG uptake in the PCC/Precuneus region, 18 F-Florbetapir uptake, CSF Aβ42, CSF p-tau, and 18 F-Flortaucipir uptake in differentiating AD from cognitively normal individuals. 18 F-FDG-PET and its combination with CSF p-tau/ Aβ42 ratio showed the highest predictive power for disease severity. The study underscores the potential of integrating 18 F-FDG-PET with CSF biomarkers to enhance the diagnosis, prognosis, and monitoring of AD, highlighting the complexity and regional specificity of biomarker interactions in neurodegeneration.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.